This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH

Ticker(s): MDGL

Who's the expert?

Institution: Massachusetts General Hospital 

  • Director of Hepatology and Liver Center & Vice Chief of Gastroenterology at Massachusetts General Hospital.
  • Treats 75 patients with PSC and 400 patients with NASH.
  • Research interest in liver disease pathogenesis in persons with HIV, viral hepatitis, and defining biomarkers and gene signatures for persons at high risk for liver disease progression and liver cancer.

Interview Questions

Roughly how many patients do you see monthly with NASH?

Added By: dami_admin

What are your thoughts on the data from the MAESTRO-NASH phase 3 trial of resmetirom? 

Added By: dami_admin

A doctor had some criticism to the data, including the level of efficacy not being super high and some side effect issues. How excited are you for the data, and how well do you think this did, relative to your expectations?

Added By: slingshot_insights

Do you think that there is a need for combination therapy in this space, or is the nature of this disease not dramatic enough to warrant additional therapy?

Added By: slingshot_insights

The doctor had a couple of criticisms of this study, including that 11 patients were lost to Covid and 40 or 50 were missing from another number in the treatment. Do you think this will affect the data?

Added By: slingshot_insights

On a scale from 1 to 10, where would you say you are on this matter of data that just came out?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.